Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study-Reference-Cited by-同舟云学术

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study

Published:2018-03 Issue:3 Volume:29 Page:646-653
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Swain S.M.,Ewer M.S.,Viale G.,Delaloge S.,Ferrero J.-M.,Verrill M.,Colomer R.,Vieira C.,Werner T.L.,Douthwaite H.,Bradley D.,Waldron-Lynch M.,Kiermaier A.,Eng-Wong J.,Dang C.

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/3/646/24530834/mdx773.pdf

Reference32 articles.

1. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J Clin Oncol,2013

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012